<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Bayer Ag Na — News on 6ix</title>
    <link>https://6ix.com/company/bayer-ag-na</link>
    <description>Latest news and press releases for Bayer Ag Na on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 20 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/bayer-ag-na" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ffbe78dffbe2df13390f.webp</url>
      <title>Bayer Ag Na</title>
      <link>https://6ix.com/company/bayer-ag-na</link>
    </image>
    <item>
      <title>AskBio&apos;s Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease</title>
      <link>https://6ix.com/company/bayer-ag-na/news/askbios-viralgen-to-supply-commercial-scale-drug-product-for-regenerate-pd-investigational-gene-therapy-phase-ii-trial-for-parkinsons-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/askbios-viralgen-to-supply-commercial-scale-drug-product-for-regenerate-pd-investigational-gene-therapy-phase-ii-trial-for-parkinsons-disease</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 GMT</pubDate>
      <description>Berlin, Germany, and Durham, N.C., USA, April 20, 2026 (GLOBE NEWSWIRE) -- Not intended for UK Media Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that it has introduced its proprietary, commercially ready manufacturing process to supply ametefg</description>
    </item>
    <item>
      <title>Bayer Canada Supports New School of Medicine at Simon Fraser University (SFU) With Full Tuition Entrance Award for Inaugural Class</title>
      <link>https://6ix.com/company/bayer-ag-na/news/bayer-canada-supports-new-school-of-medicine-at-simon-fraser-university-sfu-with-full-tuition-entrance-award-for-inaugural-class</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-canada-supports-new-school-of-medicine-at-simon-fraser-university-sfu-with-full-tuition-entrance-award-for-inaugural-class</guid>
      <pubDate>Wed, 15 Apr 2026 20:33:00 GMT</pubDate>
      <description>MISSISSAUGA, Ontario, April 15, 2026--Bayer Canada is proud to support the Simon Fraser University (SFU) School of Medicine - the first medical school in Western Canada in nearly 60 years. The new school is dedicated to help improve primary care and the critical shortage of family doctors in British Columbia, where approximately 800,000 residents lack access to a primary care physician.</description>
    </item>
    <item>
      <title>AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure</title>
      <link>https://6ix.com/company/bayer-ag-na/news/askbio-announces-completion-of-enrollment-in-phase-2-clinical-trial-of-ab-1002-investigational-gene-therapy-for-heart-failure</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/askbio-announces-completion-of-enrollment-in-phase-2-clinical-trial-of-ab-1002-investigational-gene-therapy-for-heart-failure</guid>
      <pubDate>Wed, 01 Apr 2026 06:40:00 GMT</pubDate>
      <description>Durham, N.C., April 01, 2026 (GLOBE NEWSWIRE) -- Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptomsInitial results are expected in the first half of 2027Completion of enrollment marks significant milestone in progression of heart failure clinical program and included the largest number of participants to date to receive AB-10</description>
    </item>
    <item>
      <title>National Advertising Division Recommends Bayer Modify or Discontinue Certain One A Day Men’s Pre-Conception Health Complete Multivitamin Claims</title>
      <link>https://6ix.com/company/bayer-ag-na/news/national-advertising-division-recommends-bayer-modify-or-discontinue-certain-one-a-day-mens-pre-conception-health-complete-multivitamin-claims</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/national-advertising-division-recommends-bayer-modify-or-discontinue-certain-one-a-day-mens-pre-conception-health-complete-multivitamin-claims</guid>
      <pubDate>Tue, 31 Mar 2026 15:45:00 GMT</pubDate>
      <description>Following a challenge brought by OLLY PBC, BBB National Programs’ National Advertising Division recommended that Bayer HealthCare LLC discontinue or modify certain claims for its One A Day® Men’s Pre-Conception Health Complete Multivitamin, a product marketed for men who are trying to conceive.New York, NY, March 31, 2026 (GLOBE NEWSWIRE) -- Following a challenge brought by OLLY PBC, BBB National Programs’ National Advertising Division recommended that Bayer HealthCare LLC discontinue or modify</description>
    </item>
    <item>
      <title>Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential</title>
      <link>https://6ix.com/company/bayer-ag-na/news/bayer-announces-leadership-change-within-pharmaceuticals-worldwide-markets-organization-in-the-us-to-support-companys-full-growth-potential-1</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-announces-leadership-change-within-pharmaceuticals-worldwide-markets-organization-in-the-us-to-support-companys-full-growth-potential-1</guid>
      <pubDate>Tue, 31 Mar 2026 15:30:00 GMT</pubDate>
      <description>BERLIN, March 31, 2026--Bayer today announced a leadership change within its Pharmaceuticals’ Worldwide Markets organization to accelerate the strong performance and growth of its key pharmaceutical products in the U.S.</description>
    </item>
    <item>
      <title>Bayer Crop Science Canada Redefines Canola Innovation With New &quot;Advancing Better Canola&quot; Initiative</title>
      <link>https://6ix.com/company/bayer-ag-na/news/bayer-crop-science-canada-redefines-canola-innovation-with-new-advancing-better-canola-initiative</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-crop-science-canada-redefines-canola-innovation-with-new-advancing-better-canola-initiative</guid>
      <pubDate>Thu, 26 Mar 2026 15:30:00 GMT</pubDate>
      <description>CALGARY, Alberta, March 26, 2026--Bayer Crop Science Canada launches Advancing Better Canola (ABCs), an industry-wide initiative to challenge and redefine how it thinks about canola innovation in support of Canadian farmers. Throughout 2026, the Bayer ABCs will drive dialogue, collaboration, and advocacy, while integrating genetics, agronomy, crop protection, and digital tools to better understand how to enhance its role in canola.</description>
    </item>
    <item>
      <title>Bayer Crop Science Launches 2026 Opportunity Scholarship Program</title>
      <link>https://6ix.com/company/bayer-ag-na/news/bayer-crop-science-launches-2026-opportunity-scholarship-program</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-crop-science-launches-2026-opportunity-scholarship-program</guid>
      <pubDate>Mon, 16 Mar 2026 15:00:00 GMT</pubDate>
      <description>CALGARY, Alberta, March 16, 2026--Bayer Crop Science Canada is excited to support the future of Canadian agriculture with its 2026 Bayer Crop Science Opportunity Scholarship. Through the scholarship, students entering post-secondary education in agriculture, food science or culinary arts are eligible for one of 12 scholarships valued at $5000 (CAD), with preference given to two applicants of Canadian Indigenous heritage.</description>
    </item>
    <item>
      <title>KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease</title>
      <link>https://6ix.com/company/bayer-ag-na/news/kerendiar-finerenone-meets-primary-endpoint-in-investigational-phase-iii-find-ckd-study-in-patients-with-non-diabetic-chronic-kidney-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/kerendiar-finerenone-meets-primary-endpoint-in-investigational-phase-iii-find-ckd-study-in-patients-with-non-diabetic-chronic-kidney-disease</guid>
      <pubDate>Mon, 16 Mar 2026 07:30:00 GMT</pubDate>
      <description>WHIPPANY, N.J., March 16, 2026--The Phase III study FIND-CKD (NCT05047263) — investigating the efficacy and safety of KERENDIA® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD) — has met its primary endpoint.1 The results demonstrated a statistically significant improvement versus placebo in the primary efficacy outcome of estimated glomerular filtration rate (eGFR) slope, defined as the mean annual rate of change from ba</description>
    </item>
    <item>
      <title>NurExone Announces Corporate Updates</title>
      <link>https://6ix.com/company/bayer-ag-na/news/nurexone-announces-corporate-updates-1</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/nurexone-announces-corporate-updates-1</guid>
      <pubDate>Wed, 11 Mar 2026 12:28:00 GMT</pubDate>
      <description>Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement ClosingTORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced several developments supporting its planned growth, increasing awareness in Europe, and</description>
    </item>
    <item>
      <title>Missouri Court Grants Preliminary Approval of Roundup™ Class Settlement to Resolve Current and Future Claims</title>
      <link>https://6ix.com/company/bayer-ag-na/news/missouri-court-grants-preliminary-approval-of-rounduptm-class-settlement-to-resolve-current-and-future-claims</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/missouri-court-grants-preliminary-approval-of-rounduptm-class-settlement-to-resolve-current-and-future-claims</guid>
      <pubDate>Wed, 04 Mar 2026 17:37:00 GMT</pubDate>
      <description>ST. LOUIS, March 04, 2026--Today, a judge in the Circuit Court of the City of St. Louis, Missouri granted preliminary approval of a class action settlement to resolve current and potential future Roundup claims alleging non-Hodgkin lymphoma (NHL) injuries. The motion was filed by leading plaintiff law firms representing the class.</description>
    </item>
    <item>
      <title>New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments</title>
      <link>https://6ix.com/company/bayer-ag-na/news/new-fda-510k-clearance-expands-bayers-medradr-mrxperion-mr-injection-system-support-across-diverse-range-of-mr-environments-8</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/new-fda-510k-clearance-expands-bayers-medradr-mrxperion-mr-injection-system-support-across-diverse-range-of-mr-environments-8</guid>
      <pubDate>Wed, 04 Mar 2026 13:00:00 GMT</pubDate>
      <description>WHIPPANY, N.J., March 04, 2026--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments.</description>
    </item>
    <item>
      <title>Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer</title>
      <link>https://6ix.com/company/bayer-ag-na/news/bayer-reports-results-for-the-investigational-targeted-radionuclide-therapy-225ac-psma-trillium-in-advanced-metastatic-prostate-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-reports-results-for-the-investigational-targeted-radionuclide-therapy-225ac-psma-trillium-in-advanced-metastatic-prostate-cancer</guid>
      <pubDate>Fri, 27 Feb 2026 17:43:00 GMT</pubDate>
      <description>BERLIN, February 27, 2026--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy (TAT) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The dose for expansion was successfully identified, with ≥80% of patients achieving a PSA50 response at the expansion dose.</description>
    </item>
    <item>
      <title>Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases</title>
      <link>https://6ix.com/company/bayer-ag-na/news/bayers-xofigor-radium-223-dichloride-plus-enzalutamide-demonstrates-significant-overall-survival-benefit-in-peace-3-trial-in-patients-with-metastatic-castration-resistant-prostate-cancer-with-bone-metastases</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayers-xofigor-radium-223-dichloride-plus-enzalutamide-demonstrates-significant-overall-survival-benefit-in-peace-3-trial-in-patients-with-metastatic-castration-resistant-prostate-cancer-with-bone-metastases</guid>
      <pubDate>Thu, 26 Feb 2026 16:28:00 GMT</pubDate>
      <description>WHIPPANY, N.J., February 26, 2026--Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases</description>
    </item>
    <item>
      <title>Bayer Alleges J&amp;J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&amp;J’s ERLEADA</title>
      <link>https://6ix.com/company/bayer-ag-na/news/bayer-alleges-jandjs-claims-regarding-nubeqar-are-deeply-flawed-and-intentionally-aimed-at-boosting-sales-of-jandjs-erleada</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-alleges-jandjs-claims-regarding-nubeqar-are-deeply-flawed-and-intentionally-aimed-at-boosting-sales-of-jandjs-erleada</guid>
      <pubDate>Mon, 23 Feb 2026 15:28:00 GMT</pubDate>
      <description>WHIPPANY, N.J., February 23, 2026--Bayer Alleges J&amp;J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&amp;J’s ERLEADA</description>
    </item>
    <item>
      <title>Bayer, John Deere Further Integrate FieldView and Operations Center to Improve Customer Experience for 2026 Season</title>
      <link>https://6ix.com/company/bayer-ag-na/news/bayer-john-deere-further-integrate-fieldview-and-operations-center-to-improve-customer-experience-for-2026-season-1</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-john-deere-further-integrate-fieldview-and-operations-center-to-improve-customer-experience-for-2026-season-1</guid>
      <pubDate>Mon, 23 Feb 2026 15:00:00 GMT</pubDate>
      <description>ST. LOUIS, February 23, 2026--Bayer and John Deere today announced a new capability that simplifies how U.S. farmers and advisors move from agronomic decisions to precise execution in the field. Beginning this season, customers can wirelessly transfer FieldView™ prescriptions to create Work Plans in Operations Center™. This eliminates the need for thumb drives and other manual steps that slow down field activities and increase the risk of errors.</description>
    </item>
    <item>
      <title>Monsanto Announces Roundup™ Class Settlement Agreement to Resolve Current and Future Claims</title>
      <link>https://6ix.com/company/bayer-ag-na/news/monsanto-announces-rounduptm-class-settlement-agreement-to-resolve-current-and-future-claims</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/monsanto-announces-rounduptm-class-settlement-agreement-to-resolve-current-and-future-claims</guid>
      <pubDate>Tue, 17 Feb 2026 16:50:00 GMT</pubDate>
      <description>LEVERKUSEN, Germany &amp; ST. LOUIS, February 17, 2026--Today, Monsanto announced a proposed U.S. nationwide class settlement designed to resolve current and future Roundup™ claims alleging Non-Hodgkin lymphoma (NHL) injuries through a long-term claims program. Leading plaintiff law firms representing the class filed a motion today seeking preliminary approval of the settlement in the Circuit Court of the City of St. Louis, Missouri. The proposed class combined with Supreme Court review in the Durne</description>
    </item>
    <item>
      <title>Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month</title>
      <link>https://6ix.com/company/bayer-ag-na/news/bayer-aspirin-partners-celebrity-chef-130100163</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-aspirin-partners-celebrity-chef-130100163</guid>
      <pubDate>Thu, 12 Feb 2026 13:01:00 GMT</pubDate>
      <description>WHIPPANY, N.J., February 12, 2026--This American Heart Month, Bayer® Aspirin continues its mission to help people uncover the heart health risk factors they may not see with the launch of the Heart to Heart Bistro presented by Bayer® Aspirin. Created in partnership with Celebrity Chef, Jeff Mauro, the immersive dark dining experience invites Americans to confront one of the most dangerous and often overlooked barriers to heart health – denial – by bringing the unseen risk factors of cardiovascul</description>
    </item>
    <item>
      <title>Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo</title>
      <link>https://6ix.com/company/bayer-ag-na/news/bayer-asundexian-demonstrated-substantial-26-171500588</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-asundexian-demonstrated-substantial-26-171500588</guid>
      <pubDate>Thu, 05 Feb 2026 17:15:00 GMT</pubDate>
      <description>NEW ORLEANS, February 05, 2026--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibitor asundexian (50mg) compared to placebo, both in combination with antiplatelet therapy. Asundexian significantly reduced ischemic stroke by 26% (csHR 0.74; 95% CI 0.65–0.84; p&lt;.0001), in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase in</description>
    </item>
    <item>
      <title>Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign</title>
      <link>https://6ix.com/company/bayer-ag-na/news/bayer-teams-up-with-former-professional-quarterback-tony-romo-on-highlights-real-campaign</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-teams-up-with-former-professional-quarterback-tony-romo-on-highlights-real-campaign</guid>
      <pubDate>Thu, 29 Jan 2026 13:30:00 GMT</pubDate>
      <description>WHIPPANY, N.J., January 29, 2026--Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign</description>
    </item>
    <item>
      <title>Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada</title>
      <link>https://6ix.com/company/bayer-ag-na/news/bayer-investing-more-than-dollar45m-cad-to-build-world-class-canola-research-and-development-facility-in-canada</link>
      <guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-investing-more-than-dollar45m-cad-to-build-world-class-canola-research-and-development-facility-in-canada</guid>
      <pubDate>Tue, 27 Jan 2026 16:00:00 GMT</pubDate>
      <description>CALGARY, Alberta, January 27, 2026--Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada’s leadership in canola innovation by establishing a cutting-edge canola innovation centre. Located in Winnipeg, Manitoba, the facility will house seed development work for canola, camelina and winter canola, focusing on trait integration, yield trial seed processing and seed quality analysis.</description>
    </item>
  </channel>
</rss>